These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 21404136)

  • 61. Anterior mediastinal solid tumours in adults: characterisation using dynamic contrast-enhanced MRI, diffusion-weighted MRI, and FDG-PET/CT.
    Yabuuchi H; Matsuo Y; Abe K; Baba S; Sunami S; Kamitani T; Yonezawa M; Yamasaki Y; Kawanami S; Nagao M; Okamoto T; Nakamura K; Yamamoto H; Sasaki M; Honda H
    Clin Radiol; 2015 Nov; 70(11):1289-98. PubMed ID: 26272529
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma.
    Jajamovich GH; Valiathan CR; Cristescu R; Somayajula S
    J Neurooncol; 2016 Sep; 129(2):289-300. PubMed ID: 27393347
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema.
    Server A; Kulle B; Maehlen J; Josefsen R; Schellhorn T; Kumar T; Langberg CW; Nakstad PH
    Acta Radiol; 2009 Jul; 50(6):682-9. PubMed ID: 19449234
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Differentiation between primary central nervous system lymphoma and glioblastoma: a comparative study of parameters derived from dynamic susceptibility contrast-enhanced perfusion-weighted MRI.
    Nakajima S; Okada T; Yamamoto A; Kanagaki M; Fushimi Y; Okada T; Arakawa Y; Takagi Y; Miyamoto S; Togashi K
    Clin Radiol; 2015 Dec; 70(12):1393-9. PubMed ID: 26382744
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography.
    Mori T; Nomori H; Ikeda K; Kawanaka K; Shiraishi S; Katahira K; Yamashita Y
    J Thorac Oncol; 2008 Apr; 3(4):358-64. PubMed ID: 18379353
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI.
    Rakheja R; Chandarana H; DeMello L; Jackson K; Geppert C; Faul D; Glielmi C; Friedman KP
    AJR Am J Roentgenol; 2013 Nov; 201(5):1115-9. PubMed ID: 24147485
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Can morphological MRI differentiate between primary central nervous system lymphoma and glioblastoma?
    Malikova H; Koubska E; Weichet J; Klener J; Rulseh A; Liscak R; Vojtech Z
    Cancer Imaging; 2016 Nov; 16(1):40. PubMed ID: 27894359
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Radiomics features to distinguish glioblastoma from primary central nervous system lymphoma on multi-parametric MRI.
    Kim Y; Cho HH; Kim ST; Park H; Nam D; Kong DS
    Neuroradiology; 2018 Dec; 60(12):1297-1305. PubMed ID: 30232517
    [TBL] [Abstract][Full Text] [Related]  

  • 69. First-in-Man Noninvasive Initial Diagnostic Approach of Primary CNS Lymphoma Versus Glioblastoma Using PET With 18 F-Fludarabine and l -[methyl- 11 C]Methionine.
    Postnov A; Toutain J; Pronin I; Valable S; Gourand F; Kalaeva D; Vikhrova N; Pyzhik E; Guillouet S; Kobyakov G; Khokholova E; Pitskhelauri D; Usachev D; Maryashev S; Rizhova M; Potapov A; Derlon JM
    Clin Nucl Med; 2022 Aug; 47(8):699-706. PubMed ID: 35485864
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
    Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Diagnostic and prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging.
    Baba S; Isoda T; Maruoka Y; Kitamura Y; Sasaki M; Yoshida T; Honda H
    J Nucl Med; 2014 May; 55(5):736-42. PubMed ID: 24665089
    [TBL] [Abstract][Full Text] [Related]  

  • 72. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up.
    Palmedo H; Urbach H; Bender H; Schlegel U; Schmidt-Wolf IG; Matthies A; Linnebank M; Joe A; Bucerius J; Biersack HJ; Pels H
    Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):164-8. PubMed ID: 16220304
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Differentiation of glioblastoma multiforme, metastases and primary central nervous system lymphomas using multiparametric perfusion and diffusion MR imaging of a tumor core and a peritumoral zone-Searching for a practical approach.
    Neska-Matuszewska M; Bladowska J; Sąsiadek M; Zimny A
    PLoS One; 2018; 13(1):e0191341. PubMed ID: 29342201
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Dynamic MRI, dynamic multidetector-row computed tomography (MDCT), and coregistered 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/CT: comparative study of capability for management of pulmonary nodules.
    Ohno Y; Koyama H; Takenaka D; Nogami M; Maniwa Y; Nishimura Y; Ohbayashi C; Sugimura K
    J Magn Reson Imaging; 2008 Jun; 27(6):1284-95. PubMed ID: 18504748
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Machine learning applications for the differentiation of primary central nervous system lymphoma from glioblastoma on imaging: a systematic review and meta-analysis.
    Nguyen AV; Blears EE; Ross E; Lall RR; Ortega-Barnett J
    Neurosurg Focus; 2018 Nov; 45(5):E5. PubMed ID: 30453459
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Tumor hypoxia and microscopic diffusion capacity in brain tumors: a comparison of (62)Cu-Diacetyl-Bis (N4-Methylthiosemicarbazone) PET/CT and diffusion-weighted MR imaging.
    Hino-Shishikura A; Tateishi U; Shibata H; Yoneyama T; Nishii T; Torii I; Tateishi K; Ohtake M; Kawahara N; Inoue T
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1419-27. PubMed ID: 24719157
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Glucose-corrected standardized uptake value in the differentiation of high-grade glioma versus post-treatment changes.
    Nozawa A; Rivandi AH; Kanematsu M; Hoshi H; Piccioni D; Kesari S; Hoh CK
    Nucl Med Commun; 2015 Jun; 36(6):573-81. PubMed ID: 25714806
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Response to chemotherapy in gastric adenocarcinoma with diffusion-weighted MRI and (18) F-FDG-PET/CT: correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade.
    Giganti F; De Cobelli F; Canevari C; Orsenigo E; Gallivanone F; Esposito A; Castiglioni I; Ambrosi A; Albarello L; Mazza E; Gianolli L; Staudacher C; Del Maschio A
    J Magn Reson Imaging; 2014 Nov; 40(5):1147-57. PubMed ID: 24214734
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET.
    Tsujikawa T; Yoshida Y; Kudo T; Kiyono Y; Kurokawa T; Kobayashi M; Tsuchida T; Fujibayashi Y; Kotsuji F; Okazawa H
    J Nucl Med; 2009 Oct; 50(10):1598-604. PubMed ID: 19759112
    [TBL] [Abstract][Full Text] [Related]  

  • 80. PET/MRI for the evaluation of patients with lymphoma: initial observations.
    Heacock L; Weissbrot J; Raad R; Campbell N; Friedman KP; Ponzo F; Chandarana H
    AJR Am J Roentgenol; 2015 Apr; 204(4):842-8. PubMed ID: 25794075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.